News

At the end of the study, Lexapro patients demonstrated greater improvement than Cymbalta patients as measured by a standard depression rating system known as MADRS (Montgomery and Aasberg

NB S101 contains strontium malonate as its active ingredient. The primary endpoint of the study is the change in patients' bone resorption. Osteologix plans to enroll postmenopausal women

In six-week trials, bifeprunox improved symptoms in patients with acute exacerbations of schizophrenia but showed a smaller mean effect than did active references compared to placebo. Bifeprunox also

The trial is designed to evaluate PD-02's potential to slow the progression of Parkinson's disease. PD-02 is Avicena's proprietary therapeutic that has demonstrated the potential to improve neurological

ArQule also updated progress in its other clinical programs. These include three phase II trials with the first-generation E2F-1 compound, ARQ 501, as monotherapy in leiomyosarcoma and head

Enhanze Technology is Halozyme's proprietary drug delivery technology based on its recombinant human hyaluronidase (rHuPH20). rHuPH20 is an analogue of a human enzyme that temporarily clears space in

The FDA approved the prescription-to-over-the-counter (OTC) switch of MiraLAX in October. The FDA also ruled that MiraLAX will have marketing exclusivity for three years before any generic OTC

Pooled analyses from a number of phase III studies showed significant improvements in blood sugar control among patients in this age group when treated with Galvus without the

ReNeuron has successfully extracted stem cells from the developing brain of a 12 week old aborted fetus. The company plans to use the stem cells, known as ReN001,